What accelerates (and what delays) the response to an antidepressant — the role of psychiatric management

A complaint I frequently hear from patients arriving at the office for the first time is: “I’ve taken antidepressants before, and they didn’t work for me.” A short sentence with considerable weight. It usually comes with resignation — the impression that pharmacotherapy is not a viable option, that maybe the case is resistant, that the next step would have to be a heavier treatment or an acceptance that “some people don’t respond.”

Most of the time when I investigate these histories, the scenario turns out to be different. The medication itself was usually a reasonable option for the case. What was missing was management. Refined choice of molecule, dose titration in the right timeframe, sufficient duration for the response to establish itself, an active strategy for side effects that appeared in the first weeks. Without these elements, the antidepressant does not work the way it could — and the patient leaves with the impression that the molecule failed when what actually failed was the care around it.

This text is about what well-conducted clinical management changes in the time to response, in tolerability, and in the real chance of sustaining treatment to the end.

The first factor: choosing the right molecule

There are more than fifteen antidepressants available for clinical use in Brazil today, distributed across several pharmacological classes. Each class has its own profile of efficacy by predominant symptom, its own profile of common side effects, its own profile of interactions with other medications, and its own speed of response.

The first factor that separates good management from generic management is choosing which class, and which specific molecule within that class, best matches the patient’s particular clinical picture. A patient with predominantly anxious depression will respond better to a selective serotonin reuptake inhibitor, and within that class will probably tolerate escitalopram better than fluoxetine, given the half-life profile. A patient with apathetic depression, low energy, and preserved sleep will likely respond better to bupropion, which acts on dopamine and norepinephrine, than to a serotonergic antidepressant. A patient with insomnia and reduced appetite as prominent symptoms often benefits from mirtazapine, which improves both by its receptor profile. A patient with cognitive complaints alongside depression may respond well to vortioxetine, which has documented pro-cognitive effect.

Generic choice — “prescribe sertraline for everyone with depression” — works part of the time, but leaves out precisely the customization that separates response of 40% from response of 80%. And that customization requires clinical repertoire built through years of specific psychiatric practice.

The second factor: well-titrated dose at the right timing

Antidepressant prescribed at initial dose and kept at that dose for weeks without adjustment is a common recipe for suboptimal treatment. Most antidepressants have a therapeutic-dose window that requires progressive up-titration until the patient is actually treated — not merely medicated.

This requires close follow-up in the first weeks. The initial dose of sertraline is 50 mg, and that dose already produces a therapeutic signal in many patients — but for a significant share, the effective dose will be between 100 and 200 mg. If no one adjusts the dose based on partial response, the patient may stay for months on 50 mg with incomplete improvement, thinking the molecule is not for them. The physician who follows the patient weekly or biweekly in the first eight weeks, adjusts the dose based on what the patient reports, and recognizes the right moment to go up, produces a more complete and faster response than the physician who prescribes an initial dose and reassesses three months later.

The general clinical rule is: if there was partial response at four to six weeks, raise the dose. If there was no sign at all at six weeks on the optimal dose, consider switching. Keeping a subtherapeutic dose for three months waiting for “just a little more” costs time the patient should not be losing.

The third factor: active management of side effects

A substantial share of early treatment drop-outs happen in the first two weeks — precisely when the therapeutic response has not yet arrived but the transient side effects are already present. Nausea, drowsiness or paradoxical insomnia, paradoxical initial anxiety, decreased libido, appetite changes. If the patient faces this alone, with the generic advice to “hold on, it will pass,” a good share gives up before finding out whether the medication would have worked.

Active psychiatric management treats these effects as problems to solve, not as prices to pay. Initial SSRI nausea often responds to splitting the dose into two takes, or to concurrent use of metoclopramide on specific days. Paradoxical initial anxiety can be softened with a low dose of a benzodiazepine for two or three weeks, withdrawn before it becomes dependence. Paradoxical insomnia often responds to changing the time of the dose — morning instead of evening. Excessive drowsiness may indicate that the chosen molecule is not the right one, and switching class is warranted. Decreased libido can be managed by adjusting the dose, switching the molecule to one with a better profile in this respect (agomelatine, bupropion, mirtazapine), or associating a low dose of another class.

Small differences in this handling separate the patient who continues treatment until full response from the patient who quits on day ten.

The fourth factor: sufficient duration for the picture to settle

Full response to an antidepressant is rarely linear. It is common for the patient to feel the first signs of improvement between the third and fourth week — sleep organizing, appetite returning, concentration returning — even before mood itself improves. Then comes affective improvement, which usually becomes clear between the sixth and twelfth week. And finally comes consolidation, which requires maintenance of treatment for six to twelve months after achieving full remission.

Stopping early is one of the most frequent reasons for relapse. The patient feels well in the fourth month, decides to stop, and the picture returns three to six months later. Good management includes talking about this from the start — not as an authoritarian imposition, but as part of a plan built with the patient. Treating well-treated depression is a medium-term decision, not a short-term one, and the patient needs to understand this so as not to unwittingly sabotage their own treatment.

What clinical experience teaches

What years of practice teach is that most cases arriving with the label of “resistant” or “non-responsive” are not truly resistant. They are cases where prior management fell short in one of the four points described — molecule chosen without refinement, insufficient dose, poorly managed side effects, or premature interruption.

This is not a criticism of the previous physician — it is recognition that treating depression well requires time and care that the system does not always provide. A fifteen-minute appointment every two months does not allow the type of follow-up that well-done pharmacotherapy demands. And the patient leaves with the impression that pharmacological treatment is not for them when, in reality, well-conducted pharmacological treatment has not yet been tried.

If you have already been through antidepressant treatment that “didn’t work,” it is worth considering, before assuming that pharmacotherapy is not an option: what was tried? At what dose? For how long? With what follow-up? The answer to those questions usually reveals that there is still ample room to try in a different way — with a different choice of molecule, a well-titrated dose, active management of side effects, and sufficient time for the picture to settle. That is what a well-conducted psychiatric management proposes to offer.

Dr. Leonardo Sodré is a medical psychiatrist in Brasília (CRM-DF 14,206 · RQE 14,761), with formal training and interest in psychoanalysis. This content is informational and educational, and does not replace individual clinical evaluation, diagnosis, or treatment.